Global alternative asset manager TPG has completed fundraising for its first Asia lower-middle-market growth strategy with $1.3 billion in commitments, exceeding the target for the inaugural vehicle.
The firm disclosed the final size of TPG Emerging Companies Asia, or TECA, during its third-quarter earnings call on October 29. TPG said in its official earnings materials that the fund close was part of a broader quarter in which the group raised more than $15 billion across its strategies.
Fund targets developed Asia-Pacific markets
TECA is a lower-to-middle-market growth buyout strategy focused on developed Asia-Pacific markets, primarily Australia, New Zealand, Southeast Asia and South Korea, according to TPG’s regulatory filing.
The strategy targets profitable companies that TPG believes can benefit from regional growth trends. It is designed primarily for control-oriented transactions, while allowing selective minority investments.
TPG described the new strategy as an extension of its regional platform, which began investing in Asia in 1994. The firm’s Asia business had $23.6 billion in assets under management at the end of June 2026, with investment activity spanning Australia, India, Korea and Southeast Asia.
Within TPG, TECA sits in the firm’s Growth platform alongside strategies including TPG Growth, TPG Tech Adjacencies, TPG Life Sciences Innovations and TPG Sports. The structure gives the manager a dedicated vehicle for companies that are earlier in their development or smaller than the businesses usually considered for its flagship Capital platform.
Independent fund-market coverage reported that TECA had already deployed $338 million. Its initial investments include Singapore-based eldercare operators Orange Valley and Econ Healthcare, which have been combined under One Age Care, as well as Australian home-care provider Five Good Friends.
The close takes TECA above the $742 million in commitments that TPG had reported earlier in 2026. The final amount shows that the firm added substantial capital during the year despite a difficult fundraising environment for Asia-focused private-market vehicles.
Asia fund forms part of wider capital raising
TPG raised nearly $42 billion in the first nine months of 2026 and said it now expects full-year fundraising to exceed $55 billion. That is above its original $50 billion goal.
The asset manager ended September with approximately $346 billion in total assets under management, up 21 percent from a year earlier. Fee-paying assets under management reached $190 billion, while the group reported $86 billion of dry powder available for investment.
Alongside TECA, TPG completed or advanced fundraising across several other strategies during the quarter. It said TPG Capital X and Healthcare Partners III had attracted an additional $1.7 billion, while commitments to its third Tech Adjacencies fund reached $2.5 billion. Its Peppertree digital-infrastructure strategy had raised $2.2 billion through October.
The combination of regional sector teams and a growth-equity mandate allows TECA to pursue healthcare, business-services, technology and consumer opportunities at a different scale from TPG’s larger Asia funds. Actual portfolio construction will depend on the transactions the manager can source and complete, and the fund’s final geographic and sector mix has not been disclosed.
TPG’s chief executive described TECA as an example of the firm’s effort to build adjacent strategies around established investment platforms. For Asia, the vehicle adds a dedicated route to smaller profitable companies than those typically pursued by the firm’s flagship regional buyout funds.
The fund close comes as institutional investors remain selective about Asia-Pacific private equity. Large managers with established regional teams have continued to raise capital, while newer and smaller funds have generally faced longer fundraising cycles. TECA’s above-target close is therefore evidence of demand for TPG’s strategy, but it does not by itself indicate a broad recovery in regional fundraising.
Deployment will depend on suitable transactions in the fund’s target markets. TPG has not disclosed a schedule for investing the remaining capital, and the firm’s descriptions of opportunity and expected performance are forward-looking assessments.
Temasek and GIC acquire stake in Singapore-headquartered biotech specialist CRO Novotech